Resistance to CDK4/6 inhibitors (CDKis) is emerging as a clinical challenge. Identification of the factors contributing to CDKi resistance, with mechanistic insight, is of pivotal significance. Recent studies linked aberrant FGFR signaling to CDKi resistance. However, detailed mechanisms are less clear. Based on control and FGFR1 overexpressing luminal A cell line models, we demonstrated that FGFR1 overexpression rendered the cells resistant to palbociclib. FGFR1 overexpression abolished palbociclib-mediated cell cycle arrest, as well as the attenuated palbociclib-induced inhibition of G1/S transition regulators (pRb, E2F1, and cyclin D3) and factors that promote G2/M transition (cyclin B1, cdc2/CDK1, and cdc25). Importantly, FGFR1-induced palbociclib resistance was associated with promotion of cancer cell stemness and the upregulation of Wnt/β-catenin signaling. We found that palbociclib may function as an ER agonist in MCF-7/FGFR1 cells. Upregulation of the ER-mediated transcription in MCF-7/FGFR1 cells was associated with ERα phosphorylation and enhanced receptor tyrosine kinase signaling. The combination of palbociclib with FGFR-targeting AZD4547 resulted in remarkable synergistic effects on MCF-7/FGFR1 cells, especially for the inhibition of cancer cell stemness. Our findings of FGFR1-induced palbociclib resistance, promotion of cancer stem cells and associated molecular changes advance our mechanistic understanding of CDKi resistance, which will facilitate the development of strategies targeting CDKi resistance in breast cancer treatment.
29 December 2023 in IEEE Journal of Biomedical and Health Informatics
Recent advances in large model and neuroscience have enabled exploration of the mechanism of brain activity by using neuroimaging data. Brain decoding is one of the most promising researches to further understand the human cognitive function. However, current methods excessively depends on high-quality labeled data, which brings enormous expense of collection and annotation of neural images by experts. Besides, the performance of cross-individual decoding suffers from inconsistency in data distribution caused by individual variation and different collection equipments. To address mentioned above issues, a Join Domain Adapative Decoding (JDAD) framework is proposed for unsupervised decoding specific brain cognitive state related to behavioral task. Based on the volumetric feature extraction from task-based functional Magnetic Resonance Imaging (tfMRI) data, a novel objective loss function is designed by the combination of joint distribution regularizer, which aims to restrict the distance of both the conditional and marginal probability distribution of labeled and unlabeled samples. Experimental results on the public Human Connectome Project (HCP) S1200 dataset show that JDAD achieves superior performance than other prevalent methods, especially for fine-grained task with 11.5%-21.6% improvements of decoding accuracy. The learned 3D features are visualized by Grad-CAM to build a combination with brain functional regions, which provides a novel path to learn the function of brain cortex regions related to specific cognitive task in group level.
FIFor The Alzheimer’s Disease Neuroimaging Initiative
For The Alzheimer’s Disease Neuroimaging Initiative
+3
Alzheimer’s disease (AD) is an irreversible neurodegenerative disease with a high prevalence in the elderly population over 65 years of age. Intervention in the early stages of AD is of great significance to alleviate the symptoms. Recent advances in deep learning have shown extreme advantages in computer-aided diagnosis of AD. However, most studies only focus on extracting features from slices in specific directions or whole brain images, ignoring the complementarity between features from different angles. To overcome the above problem, attention-based multi-view slice fusion (AMSF) is proposed for accurate early diagnosis of AD. It adopts the fusion of three-dimensional (3D) global features with multi-view 2D slice features by using an attention mechanism to guide the fusion of slice features for each view, to generate a comprehensive representation of the MRI images for classification. The experiments on the public dataset demonstrate that AMSF achieves 94.3% accuracy with 1.6–7.1% higher than other previous promising methods. It indicates that the better solution for AD early diagnosis depends not only on the large scale of the dataset but also on the organic combination of feature construction strategy and deep neural networks.